Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,045.00    20.00 (0.33%)
Bid:
6,040.00
Ask:
6,050.00
Spread: 10.00 (0.166%)
Market Cap: £5.16b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Form 38.5 - DCC plc

5 May 2026 11:58

RNS Number : 0863D
UBS AG (EPT)
05 May 2026
 

Ap34

 

FORM 38.5(a) (EPT/RI)

 

IRISH TAKEOVER PANEL

 

DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISHTAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022BY A CONNECTED EXEMPT PRINCIPAL TRADER WITHRECOGNISED INTERMEDIARY STATUS AND DEALING INA CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

UBS Investment Bank, London

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

DCC plc

(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1)

DCC plc

(d) Date dealing undertaken:

01 May 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

Ap35

 

(a) Purchases and sales

 

Class of relevant security (Note 3)

Purchases/ sales

Totalnumber of securities

Highest price per unit paid/ received

Lowest price per unit paid/ received

€0.25 ordinary

Buy

 

73892

58.05000 GBP

57.33544 GBP

€0.25 ordinary

Sell

 

6353

58.05000 GBP

57.33185 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities (Note 4)

Price perunit (Note 5)

€0.25 ordinary

CFD

 

Increasing a long position

200

57.9071 GBP

€0.25 ordinary

CFD

 

Increasing a long position

14

58.0488 GBP

€0.25 ordinary

CFD

 

Increasing a long position

5378

57.33184453 GBP

€0.25 ordinary

CFD

 

Reducing a long position

4

57.415 GBP

€0.25 ordinary

CFD

 

Reducing a long position

57

57.335346 GBP

€0.25 ordinary

CFD

 

Reducing a long position

72090

58.05 GBP

€0.25 ordinary

CFD

 

Reducing a long position

1235

58.04999924 GBP

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 4)

Exercise price per unit

Type  e.g. American, European etc.

Expirydate

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise priceper unit (Note 5)

 

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities)

 

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

Ap36

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

 

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

Date of disclosure:

05 May 2026

Contact name:

Richard Howard

Telephone number:

+44 (0)207 568 9128

 

Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.

 

Ap37

 

NOTES ON FORM 38.5(a)

 

1. See the definition of "connected principal trader" in Rule 2.2 of Part A of the Rules.

 

2. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

 

3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

 

4. See Rule 2.5(d) of Part A of the Rules.

 

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

 

6. If details included in a disclosure under Rule 38 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

 

For full details of disclosure requirements, see Rules 8 and 38 of the Rules. If in doubt, consult the Panel.

 

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPUVVRRNNUVRAR
Date   Source Headline
11th Jul 20247:00 amRNSAGM Trading Statement
12th Jun 202410:09 amRNS2024 Sustainability Report
12th Jun 202410:05 amRNS2024 Annual Report, Notice of AGM and Proxy Form
31st May 20245:00 pmRNSDirector/PDMR Shareholding
31st May 20244:30 pmRNSTotal Voting Rights
24th May 20245:00 pmRNSDirector/PDMR Shareholding
14th May 20247:00 amRNSResults for the year ended 31 March 2024
6th Mar 20244:52 pmRNSHolding in Company
28th Feb 20243:52 pmRNSTotal Voting Rights
7th Feb 20247:00 amRNSInterim Management Statement
31st Jan 20249:44 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSBoard and Remuneration Committee Changes
30th Nov 202311:59 amRNSTotal Voting Rights
24th Nov 20235:34 pmRNSDirector/PDMR Shareholding
20th Nov 20235:45 pmRNSDirector/PDMR Shareholding
14th Nov 20237:01 amRNSAcquisition of Progas GmbH
14th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
6th Sep 20237:00 amRNSDCC Energy Insights Day and Five New Acquisitions
31st Jul 20231:03 pmRNSTotal Voting Rights
13th Jul 20235:22 pmRNSResult of AGM
13th Jul 20237:00 amRNSAGM Trading Statement
14th Jun 202310:09 amRNS2023 Sustainability Report
14th Jun 202310:05 amRNS2023 Annual Report, Notice of AGM and Proxy Form
31st May 20234:38 pmRNSTotal Voting Rights
26th May 20234:58 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSResults for the year ended 31 March 2023
9th May 20237:00 amRNSStatement regarding Chief Executive
25th Apr 20237:00 amRNSNotice of Full Year 2023 Results
28th Feb 20239:36 amRNSTotal Voting Rights
8th Feb 20237:00 amRNSBoard Appointment
8th Feb 20237:00 amRNSInterim Management Statement
6th Jan 20235:39 pmRNSHolding in Company TR-1
30th Nov 20223:28 pmRNSTotal Voting Rights
14th Nov 20225:43 pmRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResults for the six months ended 30 September 2022
28th Oct 202212:20 pmRNSTotal Voting Rights
21st Oct 202212:19 pmRNSDirector Declaration
29th Sep 20227:16 amRNSDirector Declaration
27th Sep 20227:00 amRNSDCC acquires leading European solar distributor
16th Sep 20224:52 pmRNSHolding in Company TR-1
9th Sep 20225:10 pmRNSHolding in Company TR-1
8th Sep 20224:38 pmRNSHolding in Company TR-1
8th Sep 20227:00 amRNSDCC significantly expands in medical devices
7th Sep 20227:00 amRNSBoard Changes
16th Aug 20225:44 pmRNSHolding in Company TR-1
29th Jul 202211:02 amRNSTotal Voting Rights
26th Jul 20227:08 amRNSDirector Declaration
15th Jul 20223:52 pmRNSResult of AGM
15th Jul 20227:00 amRNSAGM Update
12th Jul 20227:00 amRNS2022 Sustainability Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.